- Ceapro (CZO) has successfully completed a research and development program with the University of Alberta
- The project is a collaboration with professor Dr. Feral Temelli at U of A
- The project demonstrated that PGX Technology can dry and purify polysaccharides like beta glucan before being impregnated with bioactives
- The research team generated unique composites known as exfoliated nanocomposites made of homogenously intertwined polymers
- Ceapro will use the findings to generate ingredients for functional food, dietary supplements, pharmaceuticals and personal care products
- Ceapro develops technology to extract ingredients from oats and other renewable plant resources
- Ceapro (CZO) is up 7.69 per cent and is currently trading at C$0.70 per share
Ceapro (CZO) has successfully completed a research and development program with the University of Alberta.
The project, a collaboration with professor Dr. Feral Temelli at U of A, will allow Ceapro to expand its utilization of PGX Technology and generate high-value ingredients for functional food, dietary supplements, personal care products and pharmaceuticals.
Unlike conventional drying and purification technologies, Ceapro’s patented Pressurized Gas eXpanded Technology can process biopolymers into open-porous polymer structures and novel biocomposites.
PGX was invented by Dr. Temelli along with Dr. Bernhard Seifried, now Senior Director of Research and Technology at Ceapro.
Results from the project demonstrated that PGX Technology can dry and purify polysaccharides like beta glucan, as well as proteins and peptides, which can then be impregnated with valuable bioactives.
Additionally, the research team generated unique composites known as exfoliated nanocomposites made of homogenously intertwined polymers with remarkable new properties.
The license from U of A provides Ceapro with exclusive worldwide rights for PGX in all industrial applications.
Gilles Gagnon, President and CEO of Ceapro, commented,
"With these important findings, we have established an expanded PGX-based product pipeline further supporting the investment decision for the commercial scale up of the PGX Technology for the processing of oat beta glucan, yeast beta glucan and alginate."
Dr. Paul Moquin, Director of Scientific Affairs and New Business Development at Ceapro, stated,
"Over the course of this project, significant inroads were made into a completely new and promising field – the simultaneous drying, purification and functionalization of proteins, peptides and enzymes.
Although it is early to totally capture the full impact that such findings will have on the development of future products, we expect that it will be disruptive to many economic sectors."
"We are very happy to successfully complete this very ambitious project, generating a lot of new information, and paving the way for new opportunities and future applications of the PGX Technology," added Dr. Temelli.
The company expects findings from this project to be published in peer-reviewed journals and scientific conferences, including three abstract presentations that have been accepted to the 18th European Meeting on Supercritical Fluids from May 4-6, 2021.
Ceapro develops technology to extract ingredients from oats and other renewable plant resources.
Ceapro (CZO) is up 7.69 per cent and is currently trading at C$0.70 per share as of 12:21 pm ET.